Industry News

SOFF: Solstad Offshore ASA's banks approve the Financing Plan
ANGLE plc. RESEARCH DEMONSTRATES POTENTIAL USE OF PARSORTIX IN ASSESSING CHEMOTHERAPY RESISTANCE. Fourth peer-reviewed publication- highlights key Parsortix advantages."/>
ANGLE PLC: Research Published in Clinical Chemistry
Bionor Pharma ASA."/>
Bionor Pharma - Preliminary result of the rights issue
Lupin Ltd., India's third largest drug maker, on Thursday said it has received approval to market generic version of Allergan Plc's Namenda extended release capsules in US market. Lupin got approval for 7 milligram, 14 mg, 21 mg and 28 mg capsules. Namenda generically called as memantine hydrochloride is used for treatment of moderate to severe dementia of the Alzheimer's type."/>
BRIEF: Lupin gets USFDA nod for generic dementia drug [Mint, New Delhi]
Apollo Hospitals Enterprise Ltd, India's largest healthcare provider, on Thursday said it has entered the medical rehabilitation services business in a joint venture with Italy-based KOS group. The equal joint venture, ApoKos, opened its first 64- bedded medical rehabilitation facility in Hyderabad, built at an estimated cost of Rs.20 crore, excluding land and building expenses. Apollo said the joint venture will be setting up similar medical..."/>
Apollo Hospitals, Italy-based KOS group to set up network of rehab facilities in India [Mint, New Delhi]
Agilent Technologies Inc. and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system. Agilent is the leading provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the..."/>
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics; Companies Collaborate in Their Aim to Accelerate Accurate Diagnosis
Amgen, one of the world's leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start, with the potential for another $600 million or more in the future. Arrowhead is based in Pasadena, California but most of its research-- including work on these two drugs-- is conducted in Madison, at 465 Science Drive, where the company has about 100 employees."/>
Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up to $673 million [The Wisconsin State Journal]
medical marijuana industry, an obvious question emerges: Where do doctors stand on pot? The medical establishment dismisses weed as scientifically untested, but some individual doctors are breaking ranks to back Amendment 2, the ballot question that will be decided Nov. 8.. The 20,000- member Florida Medical Association opposes Amendment 2."/>
Florida doctors have mixed opinions about medical marijuana [The Palm Beach Post, Fla.]
Unilife Corporation announced today that the Company will not be able to file its audited financial statements by September 30, 2016. As a result, pursuant to rules of the Australian Securities Exchange, trading in the Company's CHESS Depositary Interests on the ASX will be suspended prior to the opening of trading on the ASX on October 3, 2016, or earlier if ASX accepts the Company's request for an immediate voluntary suspension of trading..."/>
Unilife Corporation Provides Trading Update
Delcath Systems, Inc., an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering. The completion of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual..."/>
Delcath Announces Proposed Public Offering of Common Stock and Warrants
Heska Corporation, a provider of veterinary diagnostic and specialty products, today reported several key executive promotions as part of its ongoing growth initiatives. John McMahon is promoted to Chief Financial Officer. Jason Napolitano continues as Chief Operating Officer and adds the role of Chief Strategist."/>
Heska Announces Executive Promotions to Further Growth Initiatives
Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, today announced that Samira Sakhia, President of Knight Therapeutics, has joined its board of directors. Prior to her current role, Ms. Sakhia was the Chief Financial Officer of Paladin Labs."/>
Crescita Therapeutics™ Announces Changes to the Board of Directors
Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, today announced that Samira Sakhia, President of Knight Therapeutics, has joined its board of directors. Prior to her current role, Ms. Sakhia was the Chief Financial Officer of Paladin Labs."/>
Crescita Therapeutics™ Announces Changes to the Board of Directors
SunLink Health Systems, Inc. today announced that its Board of Directors has acted to protect the Company’ s valuable income tax net operating loss carryforwards by adopting a new tax benefits protection rights plan. The purpose of the rights plan is to protect shareholder value by preserving the Company’ s ability to use its NOLs in the future. The rights plan is similar to plans adopted by other public companies with significant net operating losses."/>
SunLink Adopts Shareholder Rights Plan to Protect Tax Benefits
IIROC Trading Halt - AUP (all issues)

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology691 Articles
Consumer Discretionary583 Articles
Financials451 Articles
Health Care381 Articles
Industrials380 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.